Lund, SE — August 20, 2025 — Leads & Copy — Alligator Bioscience (Nasdaq Stockholm:ATORX) shared key highlights from its R&D event held on August 19, 2025, featuring presentations on clinical progress, upcoming milestones, and strategic outlook.
Key takeaways included mitazalimab’s Phase 3 readiness, supported by encouraging overall survival data in metastatic pancreatic cancer. New biomarker data strengthens the rationale for mitazalimab in pancreatic and other solid tumors. The final data read-out from OPTIMIZE-1 is expected in Q3 2025, with continued treatment for patients and risk-based monitoring at trial sites. Investigator-initiated trials with mitazalimab are planned across various tumors in H2 2025 and H1 2026.
Additionally, the HER2 antibody HLX22, developed by Henlius, has entered a global Phase 3 trial in gastric cancers, with Alligator anticipating future royalties. Alligator is positioned to advance mitazalimab into registrational trials with a partner and explore further development options. A replay of the event is available online.
Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00
Source: Alligator Bioscience
